Prostate Cancer, Version 1.2016
James L. Mohler(Roswell Park Comprehensive Cancer Center), Andrew J. Armstrong(Duke Medical Center), Robert R. Bahnson(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Anthony V. D’Amico(Dana-Farber Brigham Cancer Center), Brian J. Davis(WinnMed), James A. Eastham(Memorial Sloan Kettering Cancer Center), Charles A. Enke(Susan Thompson Buffett Foundation), Thomas A. Farrington(Education and Research Network), Celestia S. Higano(Fred Hutch Cancer Center), Eric M. Horwitz(Fox Chase Cancer Center), Michael E. Hurwitz(Smilow Cancer Hospital), Christopher J. Kane(Moores Cancer Center), Mark H. Kawachi(City of Hope), Michael Kuettel(Roswell Park Comprehensive Cancer Center), Richard J. Lee(Massachusetts General Hospital), Joshua J. Meeks(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), David F. Penson(Vanderbilt-Ingram Cancer Center), Elizabeth R. Plimack(Moffitt Cancer Center), Julio M. Pow‐Sang(University of Colorado Cancer Center), David Raben(University of Tennessee Health Science Center), Sylvia Richey(UCSF Helen Diller Family Comprehensive Cancer Center), Mack Roach(University of California, San Francisco), Stan Rosenfeld(Sidney Kimmel Comprehensive Cancer Center), Edward M. Schaeffer(University of Michigan–Ann Arbor), Ted A. Skolarus(UCSF Helen Diller Family Comprehensive Cancer Center), Eric J. Small(University of Alabama at Birmingham), Guru Sonpavde(Cancer Institute (WIA)), Sandy Srinivas(Barnes-Jewish Hospital), Seth A. Strope(Barnes-Jewish Hospital), Jonathan D. Tward(University of Utah), Dorothy A. Shead(National Comprehensive Cancer Network), Deborah A. Freedman-Cass(National Comprehensive Cancer Network)
Cited by 655
Abstract
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease. Recommendations for disease monitoring, treatment of recurrent disease, and systemic therapy for metastatic castration-recurrent prostate cancer also are included. This article summarizes the NCCN Prostate Cancer Panel's most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-naïve disease.
Related Papers
No related papers found
Powered by citation graph analysis